Merck’s former physician-allies sowed doubt while Propecia litigation was pending

In a burst of output in the late 2010s, key opinion leaders stressed that a causal role for the drug couldn’t be proved—a welcome message for Merck’s litigation defense After FDA approved finasteride for male hair loss in 1997, the drug’s reputation stayed unblemished for a dozen years in the United States. However, the tide … Read more

Medical journals and physicians ignore conflicts of interest after a few years

Physician-researchers known as key opinion leaders have a crucial role in launching a drug into the marketplace. While Propecia litigation was underway in the 2010s, a number of opinion leaders who had helped Merck launch Proscar and Propecia wrote articles defending the drug’s safety.

Response to Dr. Ralph Trüeb’s writings on post-finasteride syndrome

A drug-induced syndrome is all in the mind, a Swiss doctor wrote. Editors of the journals had past ties to the drug maker.

Appendix: response to Trüeb

This appendix accompanies the article: Response to Dr. Ralph Trüeb’s writings on post-finasteride syndrome. Table of competing interests ← back to main article Engagements with Merck re: Propecia Skin Appendage Disorders (journal) (1) International Journal of Trichology (2) Experimental Dermatology (journal) Hair Growth and Disorders textbook (2008) Cited by Trüeb Ralph Trüeb, MD Member, Editorial … Read more